These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 1336190)
1. Inhibition of angiotensin converting enzyme by the metalloendopeptidase 3.4.24.15 inhibitor c-phenylpropyl-alanyl-alanyl-phenylalanyl-p-aminobenzoate. Chappell MC; Welches WR; Brosnihan KB; Ferrario CM Peptides; 1992; 13(5):943-6. PubMed ID: 1336190 [TBL] [Abstract][Full Text] [Related]
2. Role of angiotensin converting enzyme in the vascular effects of an endopeptidase 24.15 inhibitor. Telford SE; Smith AI; Lew RA; Perich RB; Madden AC; Evans RG Br J Pharmacol; 1995 Mar; 114(6):1185-92. PubMed ID: 7620708 [TBL] [Abstract][Full Text] [Related]
3. Synthetic inhibitors of endopeptidase EC 3.4.24.15: potency and stability in vitro and in vivo. Lew RA; Tomoda F; Evans RG; Lakat L; Boublik JH; Pipolo LA; Smith AI Br J Pharmacol; 1996 Jul; 118(5):1269-77. PubMed ID: 8818353 [TBL] [Abstract][Full Text] [Related]
4. Effects of a metalloendopeptidase-24.15. Inhibitor on renal hemodynamics and function in rats. Yang XP; Saitoh S; Scicli AG; Mascha E; Orlowski M; Carretero OA Hypertension; 1994 Jan; 23(1 Suppl):I235-9. PubMed ID: 8282366 [TBL] [Abstract][Full Text] [Related]
5. Evidence that enzymatic conversion of N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate, a specific inhibitor of endopeptidase 24.15, to N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala is necessary for inhibition of angiotensin converting enzyme. Cardozo C; Orlowski M Peptides; 1993; 14(6):1259-62. PubMed ID: 8134308 [TBL] [Abstract][Full Text] [Related]
6. A novel synthetic inhibitor of endopeptidase-24.15. Ukai Y; Li Q; Ito S; Mita S J Enzyme Inhib; 1996 Aug; 11(1):39-49. PubMed ID: 9204395 [TBL] [Abstract][Full Text] [Related]
7. Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits. Tomoda F; Lew RA; Smith AI; Madden AC; Evans RG Br J Pharmacol; 1996 Sep; 119(2):365-73. PubMed ID: 8886422 [TBL] [Abstract][Full Text] [Related]
9. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Chappell MC; Pirro NT; Sykes A; Ferrario CM Hypertension; 1998 Jan; 31(1 Pt 2):362-7. PubMed ID: 9453329 [TBL] [Abstract][Full Text] [Related]
10. Effect of chronic angiotensin converting enzyme inhibition on angiotensin I and bradykinin metabolism in rats. Stanziola L; Greene LJ; Santos RA Am J Hypertens; 1999 Oct; 12(10 Pt 1):1021-9. PubMed ID: 10560789 [TBL] [Abstract][Full Text] [Related]
11. Antinociceptive properties of inhibitors of endopeptidase 24.15. Kest B; Orlowski M; Molineaux CJ; Bodnar RJ Int J Neurosci; 1991; 56(1-4):141-9. PubMed ID: 1938129 [TBL] [Abstract][Full Text] [Related]
12. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Georgiadis D; Beau F; Czarny B; Cotton J; Yiotakis A; Dive V Circ Res; 2003 Jul; 93(2):148-54. PubMed ID: 12805239 [TBL] [Abstract][Full Text] [Related]
13. Effect of new peptide inhibitors on the ratio of angiotensin I-converting and kinin-degrading activities of dipeptidyl carboxypeptidase (angiotensin-converting enzyme). Kalinina EV; Posdnev VF; Komissarova NV; Gomazkov OA Biochemistry (Mosc); 1997 Mar; 62(3):247-50. PubMed ID: 9275297 [TBL] [Abstract][Full Text] [Related]
14. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Deddish PA; Marcic B; Jackman HL; Wang HZ; Skidgel RA; Erdös EG Hypertension; 1998 Apr; 31(4):912-7. PubMed ID: 9535414 [TBL] [Abstract][Full Text] [Related]
15. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077 [TBL] [Abstract][Full Text] [Related]
17. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries. Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724 [TBL] [Abstract][Full Text] [Related]
18. Endopeptidase 3.4.24.11 converts N-1-(R,S)carboxy-3-phenylpropyl-Ala-Ala-Phe-p-carboxyanilide into a potent inhibitor of angiotensin-converting enzyme. Williams CH; Yamamoto T; Walsh DM; Allsop D Biochem J; 1993 Sep; 294 ( Pt 3)(Pt 3):681-4. PubMed ID: 8379924 [TBL] [Abstract][Full Text] [Related]
19. Apparent kinetics of angiotensin converting enzyme: hydrolysis of [3H]benzoyl-phenylalanyl-alanyl-proline in the isolated perfused lung. Ashton JH; Pitt BR; Gillis CN J Pharmacol Exp Ther; 1985 Mar; 232(3):602-7. PubMed ID: 2983065 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme determination in plasma during therapy with converting enzyme inhibitor: two methods compared. Gorski TP; Campbell DJ Clin Chem; 1991 Aug; 37(8):1390-3. PubMed ID: 1651180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]